bisacodyl (Halflytely) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Bisacodyl is typically prescribed for relief of constipation and for the management of neurogenic bowel dysfunction as well as part of bowel preparation before medical examinations, such as for a colonoscopy. Some drugs (e.g., diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, or non-steroidal anti-inflammatory drugs) increase risk due to fluid and electrolyte changes. Most common adverse reactions (> 3%) are overall discomfort, abdominal fullness, abdominal cramping, nausea, and vomiting.   NCATS

Chemistry

  • SMILES: CC(=O)OC1=CC=C(C=C1)C(C2=CC=C(OC(C)=O)C=C2)C3=CC=CC=N3
  • InChIKey: KHOITXIGCFIULA-UHFFFAOYSA-N
  • Mol. Mass: 361.3906
  • ALogP: 4.11
  • ChEMBL Molecule:
    bisacodyl  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.0051 - $0.2510

Australia

$0.0232 - $21.2510
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( bisacodyl (Halflytely), potassium chloride (klor-con), sodium bicarbonate, sodium chloride, polyethylene glycol - other name: peg-3350, sodium chloride, sodium bicarbonate, potassium chloride and bisacodyl )

Alternative names

biolax | bisacodilo | bisacodyl | bisacodyle | bisacodylum | brocalax | correctol tablets, caplets | dulcodos | dulcolax | entrolax | feen-a-mint tablets | phenol, 4,4'-(2-pyridinylmethylene)bis-, diacetate (ester) | sk-bisacodyl | spirolax | theralax

Organizations (71)

Research & Development (69)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (1)


 

Constipation

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Abdominal Pain (Phase 2)

Alopecia (Phase 2)

Alopecia Areata (Phase 2)

Cathartics (Phase 4)

Colonic Diseases (Phase 3)

Colonic Neoplasms (Phase 4)

Colonic Polyps (Phase 3)

Colonoscopy (Phase 4)

Constipation ()

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Endoscopy (Phase 4)

Fecal Incontinence (Phase 2)

General Surgery (Phase 4)

Healthy Volunteers (Phase 3)

Hospitalization (Phase 4)

Ileus (Phase 4)

Intestinal Diseases (Phase 3)

Intestinal Neoplasms (Phase 4)

Intestine, Large (Phase 4)

Multiple Sclerosis (Phase 2)

Postoperative Complications (Phase 4)

Postoperative Nausea and Vomiting (Phase 2)

Treatment Outcome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 60
  • # of Trial Organizations: 69

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue